Healthcare

Genus plc develops pig and cattle genetics that help farmers improve productivity, health, and efficiency. Its leading PIC pig business and PRRS-resistant pig program give the company a distinctive angle, while cash generation and balance-sheet discipline add depth to the long-term picture.

GH Research is developing a short-duration psychedelic treatment for hard-to-treat depression, combining a large unmet medical need with a clean balance sheet and a differentiated clinical approach that has drawn strong market attention.

Generate Biomedicines is building an AI-driven protein medicine platform aimed at creating new biologic therapies. Partnerships, platform validation, and pipeline progress give it unusual long-term potential, even though today’s business still reflects a development-stage biotech profile.

Fortrea runs clinical trials and development services for drug and biotech companies. The appeal lies in its role within a growing outsourcing market, sizable revenue base, improving cash flow, and the possibility of a meaningful post-spin operating recovery.

4DMedical develops software-based lung imaging that aims to show how the lungs function, not just how they look. Revenue has been growing quickly and the U.S. opportunity is meaningful, but the key question is whether that momentum can turn into a scalable clinical business.

Eton Pharmaceuticals has been transforming into a more established rare disease and specialty drug platform. Revenue growth, improving margins, and positive free cash flow stand out, while newer products are giving the business a broader and more scalable commercial base.

Establishment Labs sells premium breast aesthetics devices and is gaining momentum as Motiva expands, especially after its U.S. approval. Revenue growth has reaccelerated sharply, and the company is building a broader procedure ecosystem that could reshape its scale over time.